Bootstrapping In America

Monday – Friday | 10:10 – 10:30a CT

John Flavin & Dr. Thomas Gajewski of Pyxis Oncology

Bootstrapping In America

Options involve risk and are not suitable for all investors. Please read Characteristics and Risks of Standardized Options before deciding to invest in options.

Pyxis Oncology is developing a new family of antibody-based cancer immunotherapies derived from novel insights into the biology of the tumor microenvironment. With a historically limited understanding of the distinct immunobiology of tumors and little knowledge of how current IO drugs work, the industry has struggled to build on or replicate the successes. Based on the work of Co-founder and the University of Chicago’s Dr. Gajewski, they have a new understanding of the tumor microenvironment which has unlocked multiple new avenues to restore activity to dysfunctional T cells and turn immunologically “cold” tumors “hot” and make warm tumors hotter.

Learn more about Pyxis Oncology

Bootstrapping In America More installments

See All »

Latest tastytrade Videos As of February 14

Most Shared From the last 30 days